Singapore – G1 Therapeutics, a clinical-stage oncology company, announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as Chief Commercial Officer and Stillman Hanson has been named General Counsel.

“We are excited to welcome John and Stillman to G1, and look forward to their contributions as we build out our commercial capabilities and expand our business development, legal and regulatory efforts,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer. “John’s experience building a world-class commercial oncology organization will be invaluable as our three clinical-stage programs move toward key clinical and regulatory milestones. Moreover, Stillman’s extensive life sciences corporate legal experience will be critical as the company continues to grow and evolve from research and development to commercialization.”

Mr. Demaree has more than 20 years of oncology experience, building commercial capabilities and leading multiple successful product launches. Prior to joining G1, Mr. Demaree served as Vice President, Oncology Marketing at Astellas Pharma, where he was responsible for establishing and leading the oncology marketing function, including the successful launch of Xtandi (enzalutamide). Mr. Demaree oversaw commercial strategy and execution for two approved products and three compounds in development, as well as market access and reimbursement strategy, product lifecycle management and external commercial collaborations. Previously, Mr. Demaree led oncology business development and alliance management at Abbott. He has also held marketing leadership positions at Novartis and Eli Lilly.

Mr. Hanson recently served as Associate General Counsel and Vice President at IQVIA, where he led the Quintiles legal team in the $20 billion merger of Quintiles and IMS Health to create QuintilesIMS (now IQVIA). In prior positions at Quintiles, he negotiated strategic contracts, represented Quintiles in its initial public offering and was responsible for its public company securities reporting. Before joining Quintiles in 2010, Mr. Hanson practiced corporate law, including merger and acquisitions, commercial contracting, securities reporting and corporate governance.